Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • Bitcoin CAD

    87,173.42
    +6,632.95 (+8.24%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Changes to the Board of Directors

ORPHAZYME A/S
ORPHAZYME A/S

Company announcement                                                                                        
Orphazyme A/S
No. 07/2023                                                                                                            
Ole Maaløes Vej 3
DK-2200 Copenhagen N
                                                                                                                                                      
www.orphazyme.com
Company Registration No. 32266355


Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors.

Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting. A description of the qualifications and competencies of each of the new members of the Board of Directors will be appended to the company announcement regarding the result of the Annual General Meeting.

For additional information, please contact

Orphazyme A/S

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 28 98 90 55

Attachment